Abstract
The severe shortfall in testing supplies during the initial phases of the COVID-19 pandemic and ensuing struggle to control disease spread have affirmed the need to plan rigorous optimized supply-constrained resource allocation strategies for the next inevitable novel disease epidemic. To address the challenge of optimizing limited resource usage in the face of complicated disease dynamics, we develop an integro partial differential equation disease model which incorporates realistic latent, incubation, and infectious period distributions along with limited testing supplies for identifying and quarantining infected individuals, and we analyze the influence of these elements on controllability and optimal resource allocation between two testing strategies, ‘clinical’ targeting symptomatic individuals and ‘non-clinical’ targeting non-symptomatic individuals, for reducing total infection sizes. We apply our model to not only the original, delta, and omicron COVID-19 variants, but also to generic diseases which have different offsets between latent and incubation period distributions which allow for or prevent varying degrees of presymptomatic transmission or preinfectiousness symptom onset. We find that factors which reduce controllability generally call for reduced levels of non-clinical testing, while the relationship between symptom onset, controllability, and optimal strategies is complicated. Although greater degrees of presymptomatic transmission reduce disease controllability, they may enhance or reduce the role of non-clinical testing in optimal strategies depending on other disease factors like overall transmissibility and latent period length. Our model allows a spectrum of diseases to be compared under the same lens such that the lessons learned from COVID-19 can be adapted to resource constraints in the next emerging epidemic and analyzed for optimal strategies under a consistent mathematical framework.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Center of Advanced Systems Understanding (CASUS) which is financed by Germanys Federal Ministry of Education and Research (BMBF) and by the Saxon Ministry for Science Culture and Tourism (SMWK) with tax funds on the basis of the budget approved by the Saxon State Parliament
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors